scispace - formally typeset
C

Csaba P. Kovesdy

Researcher at University of Tennessee Health Science Center

Publications -  649
Citations -  41377

Csaba P. Kovesdy is an academic researcher from University of Tennessee Health Science Center. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 92, co-authored 605 publications receiving 31462 citations. Previous affiliations of Csaba P. Kovesdy include University of California, Irvine & Semmelweis University.

Papers
More filters
Journal ArticleDOI

Fibroblast growth factor-23: what we know, what we don't know, and what we need to know

TL;DR: FGF23 has recently emerged as one of the most powerful predictors of adverse outcomes in patients with CKD and ESRD and its physiology and pathophysiology is reviewed, and putative mechanisms of action responsible for its negative effects are described and potential therapeutic strategies to treat these are described.
Journal ArticleDOI

Clinical Outcomes with Active versus Nutritional Vitamin D Compounds in Chronic Kidney Disease

TL;DR: Mixed results have been yielded regarding the potential benefits of ergocalciferol in CKD, including satisfactory to inadequate lowering of PTH level to target ranges, improving response to erythropoietin stimulating agents, and salutary effects on glycemic controls.
Journal ArticleDOI

Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation

TL;DR: In MHD patients, ferritin values above 500 ng/ml, especially in paradoxical conjunction with low ISAT, are associated with inflammation and strategies to dissociate inflammation from iron metabolism to mitigate the confounding impact of inflammation on iron and to improve iron treatment responsiveness may improve anemia management in chronic kidney disease.
Journal ArticleDOI

C.E.R.A. Corrects Anemia in Patients with Chronic Kidney Disease not on Dialysis: Results of a Randomized Clinical Trial

TL;DR: Analysis showed that subcutaneous C.E.R.A.R., a continuous erythropoietin receptor activator, once every 2 wk corrects anemia in ESA-naïve patients who are not on dialysis.